SG11202012784SA - Ask1 inhibiting agents - Google Patents
Ask1 inhibiting agentsInfo
- Publication number
- SG11202012784SA SG11202012784SA SG11202012784SA SG11202012784SA SG11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA SG 11202012784S A SG11202012784S A SG 11202012784SA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibiting agents
- ask1
- ask1 inhibiting
- agents
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690674P | 2018-06-27 | 2018-06-27 | |
PCT/US2019/039156 WO2020006031A1 (fr) | 2018-06-27 | 2019-06-26 | Agents inhibiteurs d'ask1 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012784SA true SG11202012784SA (en) | 2021-01-28 |
Family
ID=67254023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012784SA SG11202012784SA (en) | 2018-06-27 | 2019-06-26 | Ask1 inhibiting agents |
Country Status (22)
Country | Link |
---|---|
US (2) | US11814362B2 (fr) |
EP (1) | EP3814333A1 (fr) |
JP (1) | JP2021528456A (fr) |
KR (1) | KR20210024532A (fr) |
CN (1) | CN112638896A (fr) |
AR (1) | AR115636A1 (fr) |
AU (1) | AU2019291806A1 (fr) |
BR (1) | BR112020026423A2 (fr) |
CA (1) | CA3104662A1 (fr) |
CL (1) | CL2020003375A1 (fr) |
CO (1) | CO2021000782A2 (fr) |
CR (1) | CR20210049A (fr) |
EA (1) | EA202190034A1 (fr) |
IL (1) | IL279709A (fr) |
JO (1) | JOP20200318A1 (fr) |
MA (1) | MA53009A (fr) |
MX (1) | MX2020013895A (fr) |
PE (1) | PE20211379A1 (fr) |
SG (1) | SG11202012784SA (fr) |
TW (1) | TW202035389A (fr) |
UY (1) | UY38278A (fr) |
WO (1) | WO2020006031A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10669272B2 (en) | 2018-06-27 | 2020-06-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as T cell activators |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
MX2016008254A (es) * | 2013-12-20 | 2016-10-14 | Gilead Sciences Inc | Inhibidores de cinasa reguladora de la señal de apoptosis. |
WO2018151830A1 (fr) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle |
-
2019
- 2019-06-26 SG SG11202012784SA patent/SG11202012784SA/en unknown
- 2019-06-26 EA EA202190034A patent/EA202190034A1/ru unknown
- 2019-06-26 US US17/253,269 patent/US11814362B2/en active Active
- 2019-06-26 CN CN201980042586.9A patent/CN112638896A/zh active Pending
- 2019-06-26 CR CR20210049A patent/CR20210049A/es unknown
- 2019-06-26 EP EP19739494.3A patent/EP3814333A1/fr active Pending
- 2019-06-26 AR ARP190101780A patent/AR115636A1/es unknown
- 2019-06-26 MX MX2020013895A patent/MX2020013895A/es unknown
- 2019-06-26 MA MA053009A patent/MA53009A/fr unknown
- 2019-06-26 BR BR112020026423-7A patent/BR112020026423A2/pt not_active Application Discontinuation
- 2019-06-26 JP JP2020572645A patent/JP2021528456A/ja active Pending
- 2019-06-26 PE PE2020002138A patent/PE20211379A1/es unknown
- 2019-06-26 KR KR1020217000614A patent/KR20210024532A/ko unknown
- 2019-06-26 WO PCT/US2019/039156 patent/WO2020006031A1/fr unknown
- 2019-06-26 CA CA3104662A patent/CA3104662A1/fr not_active Abandoned
- 2019-06-26 UY UY0001038278A patent/UY38278A/es not_active Application Discontinuation
- 2019-06-26 AU AU2019291806A patent/AU2019291806A1/en not_active Abandoned
- 2019-06-26 JO JOP/2020/0318A patent/JOP20200318A1/ar unknown
- 2019-06-26 TW TW108122356A patent/TW202035389A/zh unknown
-
2020
- 2020-12-23 IL IL279709A patent/IL279709A/en unknown
- 2020-12-23 CL CL2020003375A patent/CL2020003375A1/es unknown
-
2021
- 2021-01-25 CO CONC2021/0000782A patent/CO2021000782A2/es unknown
-
2023
- 2023-10-05 US US18/377,125 patent/US20240109867A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20211379A1 (es) | 2021-07-27 |
MA53009A (fr) | 2021-05-05 |
CO2021000782A2 (es) | 2021-01-29 |
EA202190034A1 (ru) | 2021-04-08 |
US20210115020A1 (en) | 2021-04-22 |
TW202035389A (zh) | 2020-10-01 |
WO2020006031A1 (fr) | 2020-01-02 |
AU2019291806A1 (en) | 2021-01-07 |
US20240109867A1 (en) | 2024-04-04 |
IL279709A (en) | 2021-03-01 |
CA3104662A1 (fr) | 2020-01-02 |
EP3814333A1 (fr) | 2021-05-05 |
MX2020013895A (es) | 2021-07-21 |
UY38278A (es) | 2020-01-31 |
US11814362B2 (en) | 2023-11-14 |
AR115636A1 (es) | 2021-02-10 |
KR20210024532A (ko) | 2021-03-05 |
CL2020003375A1 (es) | 2021-09-03 |
WO2020006031A8 (fr) | 2020-09-24 |
JOP20200318A1 (ar) | 2020-12-10 |
JP2021528456A (ja) | 2021-10-21 |
CN112638896A (zh) | 2021-04-09 |
BR112020026423A2 (pt) | 2021-03-23 |
CR20210049A (es) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA187856S (en) | Caddy | |
IL269711A (en) | ASK1 inhibitory compounds and their uses | |
GB201805174D0 (en) | Compounds | |
GB201810092D0 (en) | Compounds | |
GB201801355D0 (en) | Compounds | |
GB201814169D0 (en) | Blockchain autonoumous agents | |
GB201807924D0 (en) | Compounds | |
GB201810581D0 (en) | Compounds | |
GB201808093D0 (en) | Compounds | |
GB201814151D0 (en) | Compounds | |
GB201809102D0 (en) | Compounds | |
IL279709A (en) | ASK1 inhibitory agents | |
GB201817083D0 (en) | Compounds | |
GB201812382D0 (en) | Compounds | |
GB201810071D0 (en) | Compounds | |
GB201803340D0 (en) | Compounds | |
GB201814167D0 (en) | Compounds | |
GB201801128D0 (en) | Compounds | |
GB201801130D0 (en) | Compounds | |
CA189391S (en) | Padlock | |
ZA202103582B (en) | Dna-cutting agent | |
ZA202103578B (en) | Dna-cutting agent | |
GB201811826D0 (en) | CAERvest 1 | |
GB201818410D0 (en) | Compounds | |
GB201817342D0 (en) | Compounds |